BIAF
HEALTHCAREBioAffinity Technologies Inc
$1.98-0.04 (-1.98%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving BIAF Today?
No stock-specific AI insight has been generated for BIAF yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.69$15.00
$1.98
Fundamentals
Market Cap$9M
P/E Ratio—
EPS$-8.66
Dividend Yield—
Dividend / Share—
ROE-3.0%
Profit Margin-2.4%
Debt / Equity—
Trading
Volume429K
Avg Volume (10D)—
Shares Outstanding4.5M
BIAF News
20 articles- bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® LungYahoo Finance·May 8, 2026
- bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and TreatmentYahoo Finance·Apr 28, 2026
- bioAffinity Stock Surges 113.8% in 3 Months: What's Driving the Rally?Yahoo Finance·Apr 16, 2026
- New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary BiopsyYahoo Finance·Apr 14, 2026
- bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual "Advances in Early Lung Cancer Detection" Symposium April 16Yahoo Finance·Apr 7, 2026
- bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026Yahoo Finance·Apr 1, 2026
- bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary PracticeYahoo Finance·Mar 25, 2026
- BC-Most Active StocksYahoo Finance·Mar 23, 2026
- New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive ProceduresYahoo Finance·Mar 17, 2026
- bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic CyPath® LungYahoo Finance·Mar 13, 2026
- bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive CyPath® Lung Cancer DiagnosticYahoo Finance·Mar 10, 2026
- BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?Yahoo Finance·Mar 5, 2026
- bioAffinity Technologies Presents Positive Research Findings for its Novel Diagnostic Platform Technology to Identify Optimal Therapies for Asthma PatientsYahoo Finance·Mar 3, 2026
- bioAffinity Technologies Announces Validation Study with Brooke Army Medical Center to Expand Sample Collection Options for the CyPath® Lung Noninvasive Early Detection Lung Cancer TestYahoo Finance·Feb 25, 2026
- New Case Study Highlights Ability of bioAffinity Technologies’ CyPath® Lung to Reduce Diagnostic Burden for Patients At Risk for Lung CancerYahoo Finance·Feb 19, 2026
- Clinical Utility of bioAffinity Technologies’ CyPath® Lung Test Demonstrated in Real-World Case StudyYahoo Finance·Feb 17, 2026
- bioAffinity Technologies Appoints Nationally Recognized Pulmonary and Lung Cancer Authorities to its Medical and Scientific Advisory BoardYahoo Finance·Feb 9, 2026
- bioAffinity Technologies’ Laboratory Maintains Prestigious College of American Pathologists (CAP) AccreditationYahoo Finance·Jan 7, 2026
- bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer RoundtableYahoo Finance·Dec 3, 2025
- BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider LossYahoo Finance·Nov 19, 2025
All 20 articles loaded
Price Data
Open$2.15
Previous Close$2.02
Day High$2.15
Day Low$2.00
52 Week High$15.00
52 Week Low$0.69
52-Week Range
$0.69$15.00
$1.98
Fundamentals
Market Cap$9M
P/E Ratio—
EPS$-8.66
Dividend Yield—
Dividend / Share—
ROE-3.0%
Profit Margin-2.4%
Debt / Equity—
Trading
Volume429K
Avg Volume (10D)—
Shares Outstanding4.5M
About BioAffinity Technologies Inc
bioAffinity Technologies, Inc., a biotechnology company, is engaged in the development of non-invasive diagnostic tests and specific treatments for cancer. The company is headquartered in San Antonio, Texas.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—